Company

Salarius Pharmaceuticals, Inc.

Headquarters: Houston, TX, United States

Employees: 7

CEO: Mr. David J. Arthur M.B.A.

NASDAQ: SLRX +1.02%

Market Cap

$2.5 Million

USD as of Jan. 1, 2024

Market Cap History

Salarius Pharmaceuticals, Inc. market capitalization over time

Evolution of Salarius Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Salarius Pharmaceuticals, Inc.

Detailed Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Salarius Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: SLRX wb_incandescent

Stock: FSX: FP11 wb_incandescent

Details

Headquarters:

2450 Holcombe Boulevard

Suite J-608

Houston, TX 77021

United States

Phone: 346 772 0346